Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access


Obtaining new data on the role of the antioxidant system in vitiligo in the future can contribute to the development of new effective and safe methods for combining vitiligo with an oxygen-ozone mixture with a minimal risk of side effects, as well as a short duration of treatment and low financial costs. Materials and methods. We observed 50 patients with vitiligo in the advanced stage of the disease, aged 20-59 years. Before the start of the course of ozonotherapy and after its completion in 2-4 weeks, the main indicators of the antioxidant system were studied (the following superoxide dismutase, glutathione peroxidase, glutathione, malonic dialdehyde, 8-OH-deoxyguanosine). All patients received systemic oxygen-ozone mixture therapy by intravenous injection of ozonized saline (OBS). The amount of the injected solution is 300-400 ml, the duration of the procedure is 30-60 minutes. The procedures performed 3 times a week; the course is 9-10 procedures. The tolerability of the procedures was satisfactory in all cases, no side effects were observed. Results. As a result of the treatment the stop of the progression of vitiligo was noted in 40 (80%) patients in the form of diffuse or point repigmentation, a decrease in the area of depigmented spots. This clinical picture correlated with the normalization of the indices of oxidative stress, which was manifested by a significant decrease in the level of malonic dialdehyde and 8-OH-deoxyguanosine against a background of an increase in the concentration of glutathione and glutathione peroxidase on average in 1.5 times.

Full Text

Restricted Access

About the authors

Lyudmila G. Gereykhanova

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Moscow, 119991, Russian Federation
dermatologist, postgraduate student, department of skin and venereal deseases of I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, 119991, Russian Federation.

K. M Lomonosov

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Moscow, 119991, Russian Federation

Yu. G Melnikova

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Moscow, 119991, Russian Federation


  1. Taieb A., Picardo M. The definition and assessment of vitiligo: a consensus report of the Vitiligo European Task Force Pigment Cell Res. VETF Members 2007; 20(1): 27-35.
  2. Yaghoobi R., Omidian M., Bagherani N. Vitiligo: A review of the published. J. Dermatol. 2011; 38(5): 419-31.
  3. Nordlund J.J. Vitiligo: a review of some facts lesser known about depigmentation. Indian J. Dermatol. 2011; 56(2): 180-9.
  4. Ongenea K., Van Geel N., Schepper S.D., Naeyaert J.M. Effect of vitiligo on self-reported health-related quality of life. Br. J. Dermatol. 2005; 152(6): 165-72.
  5. Taieb A., Picardo M. Epidemiology, definitions and classification. Vitiligo. Heidelberg: Springer Verlag; 2010: 20-3.
  6. Герейханова Л.Г., Ломоносов К.М., Башлакова К.А. Окислительный стресс в патогенезе витилиго и методы его коррекции. Российский журнал кожных и венерических болезней. 2016; 19(1): 167-9.
  7. Ломоносов К.М. Окислительный стресс и антиоксидантная терапия при различных заболеваниях кожи. Российский журнал кожных и венерических болезней. 2009; 12(2): 27-30.
  8. Kanwar A.J., Dogra S. Narrow-band UVB for the treatment of generalized vitiligo in children. Clin. Exp. Dermatol. 2005; 30(4): 332-6
  9. Кошелева И.В. Кислородно-озоновая терапия хронических иммунозависимых дерматозов. Available at: (accessed 14.10.2017)
  10. Valko M., Leibfritz D., Moncol J., Cronin M.T.,Mazur M. Free radicals and antioxidants in normal physiological functions and human disease. Intern. J. Biochem. Cell. Biol. 2006; 39(1): 44-84



Abstract - 47

PDF (Russian) - 0


Article Metrics

Metrics Loading ...



Copyright (c) 2017 Gereykhanova L.G., Lomonosov K.M., Melnikova Y.G.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies